Drugs / D07001
D07001
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05065957 | Mar 2022 → Jul 2026 overdue | biliary tract cancer | InnoPharmax Inc. | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06622057 | Jun 2026 → Dec 2028 expected | biliary tract cancer | InnoPharmax Inc. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | D07001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06622057 ↗ |
| Known as | D07001-softgel capsules | “D07001-softgel capsules: 3 times per week (on Days 1, 3, 5, 8, 10, 12, 15, 17, and 19 of a 21-day cycle, 9 doses per cycle).” NCT05065957 ↗ |
| Known as | gemcitabine | “D07001-softgel capsule is an oral gemcitabine.” NCT06622057 ↗ |
| Route | Oral | “eligible patients will be assigned to receive oral D07001-softgel” NCT05065957 ↗ |